TG Therapeutics, Inc.
TG Therapeutics (Nasdaq: TGTX) is a commercial-stage biotechnology company that acquires, develops and commercializes treatments for B-cell-mediated diseases. Its marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved to treat adults with relapsing forms of multiple sclerosis (RMS);… From the company’s description.
Over the twelve months to Jun 30, 2026, TG Therapeutics, Inc. reported revenue of $799.54M, up 76.1% from a year earlier, and net income of $441.49M. Its operating margin was 17.1%, and operations generated $17.88M in cash. In fiscal 2025, it reported revenue of $616.29M, up 87.3% from fiscal 2024, and net income of $447.18M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What TG Therapeutics, Inc. does
In the company’s own words
TG Therapeutics (Nasdaq: TGTX) is a commercial-stage biotechnology company that acquires, develops and commercializes treatments for B-cell-mediated diseases. Its marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved to treat adults with relapsing forms of multiple sclerosis (RMS); it is sold in the United States by TG Therapeutics and commercialized in certain markets outside the United States by Neuraxpharm. The company’s development pipeline includes intravenous and subcutaneous ublituximab programs for RMS, as well as azer-cel, an investigational CD19-directed CAR T-cell therapy being studied for progressive forms of multiple sclerosis. TG Therapeutics licenses development and commercial rights to its products and works with partners on commercialization and supply. It has no reportable operating segments and focuses primarily on multiple sclerosis within its broader B-cell disease strategy. BRIUMVI launched in the United States in January 2023, following FDA approval in December 2022. Its website is www.tgtherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1001316
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns TG Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · TG Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do TG Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of TG Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in TG Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”